The effect of pre-transplant JAK 1/2 inhibitors on outcomes of myelofibrosis patients who receive allogeneic stem cell transplant.

7072Background: The use of JAK 1/2 inhibitors (JAKi) for myelofibrosis (MF) treatment is becoming commonplace, but their impact on outcomes after hematopoietic stem cell transplant (SCT) is not wel...